BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2020 1:38:19 AM | Browse: 676 | Download: 1178
 |
Received |
|
2020-01-03 21:04 |
 |
Peer-Review Started |
|
2020-01-03 21:05 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2020-04-03 20:37 |
 |
Revised |
|
2020-07-01 20:15 |
 |
Second Decision |
|
2020-07-17 09:31 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2020-07-19 21:59 |
 |
Articles in Press |
|
2020-07-19 21:59 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2020-08-03 00:45 |
 |
Publish the Manuscript Online |
|
2020-08-21 01:38 |
ISSN |
2218-4333 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Review |
Article Title |
B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia
|
Manuscript Source |
Invited Manuscript |
All Author List |
Lindsay Wilde, Sabarina Ramanathan and Margaret Kasner |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Margaret Kasner, MD, MSc, Associate Professor, Department of Hematology and Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, 834 Chestnut St. Suite 315, Philadelphia, PA 19107, United States. margaret.kasner@jefferson.edu |
Key Words |
Acute myeloid leukemia; B-cell lymphoma-2; Venetoclax; Metabolism; Leukemic stem cell; Resistance |
Core Tip |
The B-cell lymphoma-2 inhibitor venetoclax has drastically changed the treatment paradigm for acute myeloid leukemia; however, much is unknown about mechanisms of relapse after treatment with this agent. Alterations in cellular metabolism have been identified as a potential resistance mechanism and may be able to be targeted with novel treatments. |
Publish Date |
2020-08-21 01:38 |
Citation |
Wilde L, Ramanathan S, Kasner M. B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia. World J Clin Oncol 2020; 11(8): 528-540 |
URL |
https://www.wjgnet.com/2218-4333/full/v11/i8/528.htm |
DOI |
https://dx.doi.org/10.5306/wjco.v11.i8.528 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345